Graduated from Duke in three years while studying Biomedical Engineering and working part-time. Hands-on lab experience using viral vectors to deliver genes to cells. MBA from IMD, a one year program in Lausanne, Switzerland. International network and experience including strategy, business development, project management, product development and start-ups.

Professor of Surgery and Immunology at the University of Pittsburgh Medical Center. PhD from Imperial College of London, Postdocs at Surrey University, Cancer Research UK, Veteran’s Affairs Hospital (Palo Alto), and Stanford. Consulting experience in this field includes a company with a product currently in late-stage trials. Author on more than 65 scientific publications in the field. Invented our lead technology, the WO-12.

Advanced over 50 drugs into clinical trials during 25 years of experience starting at Bristol-Myers and including Eli Lilly and several biotech companies. Managed the development of small molecules, biologics, gene therapies, and vaccines while coordinating with FDA. Author on more than 50 research articles in drug development and consultant to a range of companies. PhD from SUNY Upstate Medical University.

Former FDA Director at the Center for Biologics Evaluation and VP of Regulatory Affairs at Human Genome Sciences. Specific expertise in vaccines and gene therapy. Serves on the Steering Committee for the NIH National Gene Vector Laboratory and is a member of the Clinical and Regulatory Affairs Committee of the American Society of Gene Therapy. PhD from UNC Chapel Hill and 25 years experience across industry, academia, and government.

Clinical Oncologist and Director of Early Phase Clinical Investigation and Professor of Medicine at UC San Diego Moores Cancer Center. Recognized by the International Society of Gene Therapy and Society for Interventional Radiology. On review board of the journals Nature Cancer Gene Therapy, Gene Therapy, and Clinical Cancer Research. MD, PhD from Stanford and has treated hundreds of patients with oncolytic viruses in 23 years of practice.